Q32 Bio Inc. entered into a securities purchase agreement for a $10.5 million registered direct offering of 1,666,679 shares of common stock at $3.90 per share and pre-funded warrants to purchase 1,025,654 shares at $3.8999 per share equivalent. The net proceeds will fund working capital, research, clinical development, and advancement of bempikibart into future clinical trials for alopecia areata.
Key takeaways
Entered securities purchase agreement on February 17, 2026 with institutional investors
Issuing 1,666,679 shares of common stock at $3.90 per share
Issuing pre-funded warrants to purchase 1,025,654 shares at $3.8999 per share equivalent
Gross proceeds of approximately $10.5 million before offering expenses
Closing expected on or about February 18, 2026 subject to customary conditions
Proceeds for working capital, research, clinical development including bempikibart trials for alopecia areata